# Mosanna Therapeutics

> Mosanna Therapeutics is a clinical-stage biotech developing MOS118, a bedtime nasal spray for obstructive sleep apnea (OSA). Rather than mechanically forcing the airway open like CPAP, MOS118 is a small molecule pan-K+ channel inhibitor that reactivates the body's own negative pressure reflex - stimulating pressure-sensing nerves in the nasopharynx to increase upper airway muscle tone and reduce apnea episodes. Founded in 2022 and headquartered in Redwood City, California with an office in Basel, Switzerland, the company launched publicly in June 2025 with an $80 million Series A to advance MOS118 through Phase 2.

- **Founded:** 2022
- **Headquarters:** Redwood City, California, United States
- **Founders:** Jonathan Talbot (Co-Founder (founding CEO))
- **Team size:** Approximately 15 employees
- **Products:** MOS118
- **Notable:** Closed an $80 million Series A in June 2025 co-led by five top-tier life-science investors while emerging from stealth., Advanced MOS118, a first-in-class small molecule pan-K+ channel inhibitor, into clinical development., Recruited a leadership team with prior FDA approvals, including CEO David Weber (former Otonomy CEO, led approval of OTIPRIO).

## Products & services

- **MOS118** — A first-in-class small molecule pan-K+ channel inhibitor formulated as a microparticle-suspension nasal spray, taken at bedtime. It activates pressure-sensing nerves in the nasopharynx to trigger the negative pressure reflex, increasing upper airway dilator muscle tone and reducing apnea and hypopnea episodes throughout the night. Lead program advancing toward Phase 2.

## Achievements

- Closed an $80 million Series A in June 2025 co-led by five top-tier life-science investors while emerging from stealth.
- Advanced MOS118, a first-in-class small molecule pan-K+ channel inhibitor, into clinical development.
- Recruited a leadership team with prior FDA approvals, including CEO David Weber (former Otonomy CEO, led approval of OTIPRIO).
- Named recognition as a Venture Leader biotech via Venturelab in Switzerland.
- Assembled a board and advisory group including David White, MD, a former president of the American Academy of Sleep Medicine.

## Latest updates

- **2025-06** — Mosanna Therapeutics launched publicly with an $80 million Series A financing and appointed David Weber, Ph.D., as President and CEO to lead clinical development of MOS118.
- **2025-06** — Company outlined plans to advance MOS118 through Phase 2 development and to expand its pipeline of airway therapeutics.

## Links

- Website: https://mosanna.com
- LinkedIn: https://www.linkedin.com/company/mosanna-therapeutics

---

Profile page: https://yespress.io/mosanna-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-07-18